Pharma company – Prices Vardenafil Levitra http://pricesvardenafillevitra.com/ Thu, 12 May 2022 09:13:33 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://pricesvardenafillevitra.com/wp-content/uploads/2021/10/icon-26.png Pharma company – Prices Vardenafil Levitra http://pricesvardenafillevitra.com/ 32 32 Alzheimer’s: Delhi pharmaceutical company obtains drug candidate from Bengaluru scientists | India News https://pricesvardenafillevitra.com/alzheimers-delhi-pharmaceutical-company-obtains-drug-candidate-from-bengaluru-scientists-india-news/ Thu, 12 May 2022 02:19:00 +0000 https://pricesvardenafillevitra.com/alzheimers-delhi-pharmaceutical-company-obtains-drug-candidate-from-bengaluru-scientists-india-news/ BENGALURU: More than a year after scientists at the Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR) developed a drug molecule to prevent the mechanism that makes neurons (brain cells) dysfunctional in Alzheimer’s disease (AD), its intellectual property (IP) was transferred to a Delhi-based pharmaceutical company. Hamsa Biopharma, which will take the drug – dubbed […]]]>
BENGALURU: More than a year after scientists at the Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR) developed a drug molecule to prevent the mechanism that makes neurons (brain cells) dysfunctional in Alzheimer’s disease (AD), its intellectual property (IP) was transferred to a Delhi-based pharmaceutical company.
Hamsa Biopharma, which will take the drug – dubbed TGR63 – through trials through its US parent company IGC Pharma, hopes it can eventually be made available on the market.
TOI was the first to report on Professor T Govindaraju and the team developing ‘TGR63’ in its February 26, 2021 edition. Although treatments available on the market provide temporary relief, there are no approved drugs. which acts directly on the pathological mechanisms of Alzheimer’s disease, which the scientists of JNCASR and Hamsa believe that “TGR63” has the potential to do.
Ram Mukunda, CEO of IGC Pharma, told TOI: “We got in touch with Professor Govindaraju after hearing about the molecule, which we believe can be a game-changer, in March-April 2021. We analyzed the molecule, the study and the results and our experts found there was potential.
Drug candidate
Govindaraju, reiterating how ‘TGR63’ has the potential to stop or cure the leading cause of dementia, explained that in the Alzheimer’s disease brain, abnormal levels of naturally occurring proteins clump together to form plaques that build up between neurons and disrupt cellular function.
“…This is caused by the production and deposition of a protein called amyloid peptide (Aß) which accumulates in the central nervous system. The multifactorial nature of AD has prevented researchers from developing an effective treatment until now, but we now have a candidate that could reduce Aß toxicity,” he added.
The JNCASR has already established – through laboratory and animal (mouse) tests – that “TGR63” can rescue neuronal cells from amyloid toxicity.
“The brains of AD mice treated with “TGR63” showed a significant reduction in amyloid deposits, validating its therapeutic efficacy. The mice also showed reductions in learning deficit, memory impairment, and cognitive decline, as revealed by separate behavioral tests. These key attributes validate the potential of ‘TGR63’ as a promising drug candidate for AD,” Govindaraju reiterated.
After that
Mukunda said the company will begin testing the molecule for toxicity and absorption in primates. “Once we can document all the data and show it is safe when used in primates, which is a process that is expected to take about a year, we can proceed to phase I trials in humans. ‘male. Here we would test the safety and tolerance of the molecule in humans,” he said.
He said the company would fast-track testing and in about 12 months or so it would be ready to seek regulatory approval for phase I human trials.
“Once approved, this process should continue for another year, where we would essentially test security among different groups. While the first tests will take place in India, we may need to transfer them to the United States, Canada or South America for testing in primates and humans,” Mukunda said.
After the safety trials, the company would seek authorization to embark on phase II human trials – efficacy testing – whose protocols would be prepared in consultation with the team of Professor Govindaraju and other experts from the JNCASR .
“Phase II trials could take 24 to 30 months, after which we would be ready with a product that could help hundreds of thousands of people around the world. We are confident that the molecule works and the work done at JNCASR is truly groundbreaking,” Mukunda said.
]]>
Akums, the largest pharmaceutical contract manufacturing company, acquires the HP plant from Ankur Drugs And Pharma Ltd. https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd/ Wed, 04 May 2022 09:09:09 +0000 https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd/ Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in India, recently acquired a facility from Ankur Drugs and Pharmaceuticals Limited. The facility acquired by Akums Drugs is one of the largest drug manufacturing plants in the country. With this acquisition, Akums will increase its production capabilities for general oral tablets and oral […]]]>

Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in India, recently acquired a facility from Ankur Drugs and Pharmaceuticals Limited. The facility acquired by Akums Drugs is one of the largest drug manufacturing plants in the country. With this acquisition, Akums will increase its production capabilities for general oral tablets and oral liquids. The planned capacities of the new facility are 6 billion units of tablets and 90 million units of oral fluids per year. This facility is expected to be fully operational by the end of 2022.

Founder, Promoter and Director of Akums Drugs & Pharmaceuticals, Shri Sandeep Jain says, “What adding this new facility to our existing network means is to intensify our continuous efforts to serve our customers efficiently and better serve the nation. At Akums, we are already leading the market in many areas and therefore we also know that there is still a long way to go. With this new facility at Nalagarh in Solan, Himachal Pradesh, we are trying to fill other capacity gaps in the pharmaceutical industry.

Founder, Promoter and Director of Akums Drugs & Pharmaceuticals, Shri Sanjeev Jain said: “In 2021, our supplies accounted for approximately 12% of the total market. With this new acquisition of facilities in the state of Himachal Pradesh and our previous acquisition in Kotdwar, Uttarakhand in August 2021, we have further strengthened our total capacity. This expansion is a step towards reaching our target of 20% market share. Operations at our factory in Kotdwar started recently, while our new factory in Himachal Pradesh is expected to start operations by December 2022.”
Apart from these changes, Akums had also acquired three API facilities near Chandigarh in January 2021, all of which contribute to building its capacity and efficient upstream integrated supply chain to strengthen its market leadership position in India, as Akums manufactures about 12% of all drugs consumed in the country.



About Akums

Akums Drugs & Pharmaceuticals Ltd. is India’s largest pharmaceutical contract manufacturing company, manufacturing over 12% of Indian consumption. The organization is involved in the manufacture and export of formulations in a wide range of dosage forms and therapeutic segments. The company currently supplies almost all Indian and multinational pharmaceutical companies across the world and is one of the largest employers. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta-lactum and non-beta-lactum formulations), oral liquid dosage forms, sterile dosage forms (injectable, ocular, ear and nasal) , hormonal (oral and injectable), ointments & cosmetics, Ayurvedic, food supplements & nutraceuticals and animal health care.

Within a few years, the organization has become the icon of India’s pharmaceutical industry and currently manufactures over 12% of the country’s total medical needs. With the creme de la creme of dedicated pharmaceutical staff and standardized practices, Akums has successfully achieved national and international accreditations and established trust based on efficacy, safety and quality. The organization is certified by WHO-GMP, ISO 9001:2015, ISO 14001:2015 certificates and various international accreditations, such as; ANVISA, Brazil, NAFDAC, Nigeria, FDB, Ghana, PMPB, Malawi among others and exports to 53 countries around the world.

]]>
Open Orphan Subsidiary Signs Deal With Global Pharmaceutical Company https://pricesvardenafillevitra.com/open-orphan-subsidiary-signs-deal-with-global-pharmaceutical-company/ Wed, 04 May 2022 07:30:59 +0000 https://pricesvardenafillevitra.com/open-orphan-subsidiary-signs-deal-with-global-pharmaceutical-company/ Contract research company Open Orphan said its subsidiary hVivo had signed an agreement with a major pharmaceutical customer to manufacture a virus for use in human challenge studies. The Anonymous Client is a top-five global company, Open Orphan said. The value of the deal was not disclosed, but Open Orphan said the contract was “substantial”. […]]]>

Contract research company Open Orphan said its subsidiary hVivo had signed an agreement with a major pharmaceutical customer to manufacture a virus for use in human challenge studies.

The Anonymous Client is a top-five global company, Open Orphan said. The value of the deal was not disclosed, but Open Orphan said the contract was “substantial”.

Manufacturing has already started and work should be completed by the end of the third quarter.

Open Orphan said it was optimistic that a characterization study, which establishes the right dose of virus to cause safe and reliable infection in healthy volunteers, and a substantial human challenge study would follow completion of the manufacturing process. .

“This contract demonstrates our world-class capabilities across the entire challenge trial process, starting with virus manufacturing, through characterization study and challenge study execution. This contract illustrates our ability to leverage this to build deep and lasting relationships with our clients over long periods of time,” said Yamin Khan, Managing Director of Open Orphan.

“This contract is also another example of the company’s ability to secure repeat contracts from its existing base of Big Pharma customers, who have great confidence in our decades of experience in world-leading clinical trials. global level. With this experience coupled with our expanded offering following facility expansion, I look forward to providing additional clinical services support to the significantly expanded and growing infectious and respiratory disease market.

Open Orphan, a European rare and orphan drug advisory services platform, is the result of executive chairman Cathal Friel flipping his namesake pharmaceutical services business into Dublin-listed director of clinical drug trials Venn Life. Science.

]]>
German pharmaceutical company Merck to expand manufacturing in China https://pricesvardenafillevitra.com/german-pharmaceutical-company-merck-to-expand-manufacturing-in-china/ Sun, 01 May 2022 01:45:22 +0000 https://pricesvardenafillevitra.com/german-pharmaceutical-company-merck-to-expand-manufacturing-in-china/ A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP Merck, a Germany-based pharmaceutical company, on Thursday signed an agreement to significantly expand its manufacturing capabilities in Wuxi City, east China’s Jiangsu Province, […]]]>

A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP

A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP

Merck, a Germany-based pharmaceutical company, on Thursday signed an agreement to significantly expand its manufacturing capabilities in Wuxi City, east China’s Jiangsu Province, according to a company statement.

The company will invest nearly 100 million euros ($110 million) over six years in expanding its existing Wuxi production site to increase single-use biopharmaceutical assemblies and custom design capabilities, according to the agreement it signed with Wuxi High-tech Zone in a video conference. .

The investment is expected to create around 1,000 new jobs and be operational by 2024, the company said.

“Over the next five years, we expect strong growth in the bioprocess market, with growth in Asia in the mid-1920s and growth in China exceeding 20% ​​per year on average,” said Marc Jaffre, Managing Director of Merck’s life sciences business in China. “This strategic investment will support biotech innovation in China.”

Wuxi has developed biomedicine as its “flagship industry”, attracting AstraZeneca, General Medicine, Pfizer and more than 1,200 international biomedicine companies. In 2021, the industrial scale of biomedicine in Wuxi reached 140.9 billion yuan ($21 billion), up 20 percent year on year.

Source(s): Xinhua News Agency

]]>
British pharmaceutical company fined for tainted baby food – Jamaica Observer https://pricesvardenafillevitra.com/british-pharmaceutical-company-fined-for-tainted-baby-food-jamaica-observer/ Fri, 29 Apr 2022 14:50:54 +0000 https://pricesvardenafillevitra.com/british-pharmaceutical-company-fined-for-tainted-baby-food-jamaica-observer/ LONDON, United Kingdom (AFP) – A British pharmaceutical company was fined more than £1million on Friday for supplying contaminated food to premature babies and potentially causing “serious harm”. Nineteen infants were infected in nine hospitals in England after receiving a contaminated batch of “total parenteral nutrition” from ITH Pharma. They had all received the liquid […]]]>

LONDON, United Kingdom (AFP) – A British pharmaceutical company was fined more than £1million on Friday for supplying contaminated food to premature babies and potentially causing “serious harm”.

Nineteen infants were infected in nine hospitals in England after receiving a contaminated batch of “total parenteral nutrition” from ITH Pharma.

They had all received the liquid directly into their bloodstream because they were unable to feed themselves.

Three of the babies later died, although Southwark Crown Court in south London was told the deaths were not product-related or caused by the company.

But Judge Deborah Taylor said that in the event of the death of a premature twin, the company’s processes risk “serious damage and/or death”.

London’s Metropolitan Police launched an investigation in 2014 after the three babies died and 20 others needed treatment when they contracted sepsis.

The force said ITH Pharma was fined £1.2m ($1.5m, €1.4m) after pleading guilty to three offenses at a hearing previous.

The company admitted one charge of failing to carry out a proper and sufficient risk assessment, and two of supplying a drug “not of the nature or quality specified in the prescription”.

Chief Detective Inspector Richard Leonard, who led the investigation, paid tribute to the families of those affected.

“We salute their bravery and dignity in coming to court and reliving their most difficult times,” he said in a statement.

“We hope they can be reassured that the criminal proceedings are now complete.”

ITH Pharma, which supplies the state-run National Health Service, said it offered its condolences to the families of those affected and accepted the fine imposed by the court.

A spokesperson described the events of May 2014 as “quite exceptional”.

“Since 2008, parenteral nutrition produced by ITH has helped tens of thousands of the most vulnerable babies survive premature and complex births.”

]]>
Akums, the largest pharmaceutical contract manufacturing company, acquires the HP plant from Ankur Drugs and Pharma Ltd. to increase production capacity https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd-to-increase-production-capacity/ Thu, 28 Apr 2022 11:31:57 +0000 https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd-to-increase-production-capacity/ Previous story: Celebrate Akshaya Tritiya with the best jewelry online Akums, the largest pharmaceutical contract manufacturing company, acquires the HP plant from Ankur Drugs and Pharma Ltd. to increase production capacity Posted on April 28, 2022 Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in Indiarecently acquired a facility of Ankur Drugs […]]]>
Previous story:

Celebrate Akshaya Tritiya with the best jewelry online

Akums, the largest pharmaceutical contract manufacturing company, acquires the HP plant from Ankur Drugs and Pharma Ltd. to increase production capacity

Posted on April 28, 2022

Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in Indiarecently acquired a facility of Ankur Drugs and Pharmaceuticals Limited. The facility acquired by Akums Drugs & Pharmaceuticals Ltd is one of the largest drug manufacturing facilities in the country. With this acquisition, Akums will increase its production capabilities for general oral tablets and oral liquids. The planned capacities of the new facility are 6 billion units of tablets and 90 million units of oral fluids per year. This facility is expected to be fully operational by the end of 2022.

Founder, promoter and director, Akums Medicines and Pharmaceuticals, Shri Sandeep Jain says, “What adding this new facility means to our existing network is to intensify our ongoing efforts to serve our customers efficiently and better serve the nation. At Akums, we are already leading the market in many areas and therefore we also know that there is still a long way to go. With this new facility at Nalagarh in Solan, Himachal Pradesh, we are trying to fill other capacity gaps in the pharmaceutical industry.

Founder, promoter and director, Akums drugs and pharmaceuticals, Shri Sanjeev Jain states: “In 2021, our supplies represented approximately 12% of the total market. With this new acquisition of facilities in the state of Himachal Pradesh and our previous acquisition in Kotdwar, Uttarakhand in August 2021, we have further strengthened our total capacity. This expansion is a step towards reaching our target of 20% market share. Operations at our factory in Kotdwar started recently, while our new factory in Himachal Pradesh is expected to start operations by December 2022.”

Apart from these changes, Akums had also acquired three API facilities near Chandigarh in January 2021, all of which contribute to building its capacity and efficient upstream integrated supply chain to strengthen its market leadership position in India, as Akums manufactures about 12% of all drugs consumed in the country.

About Akums- Akums Drugs & Pharmaceuticals Ltd. is India’s largest pharmaceutical contract manufacturing company, manufacturing over 12% of Indian consumption. The organization is involved in the manufacture and export of formulations in a wide range of dosage forms and therapeutic segments. The company currently supplies almost all Indian and multinational pharmaceutical companies across the world and is one of the largest employers. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta-lactum and non-beta-lactum formulations), oral liquid dosage forms, sterile dosage forms (injectable, ocular, ear and nasal) , hormonal (oral and injectable), ointments & cosmetics, Ayurvedic, food supplements & nutraceuticals and animal health care.

Within a few years, the organization has become the icon of India’s pharmaceutical industry and currently manufactures over 12% of the country’s total medical needs. With the creme de la creme of dedicated pharmaceutical staff and standardized practices, Akums has successfully achieved national and international accreditations and established trust based on efficacy, safety and quality. The organization is certified by WHO-GMP, ISO 9001:2015, ISO 14001:2015 certificates and various international accreditations, such as; ANVISA, Brazil, NAFDAC, Nigeria, FDB, Ghana, PMPB, Malawi among others and exports to 53 countries around the world.

]]>
Akums, the largest pharmaceutical contract manufacturing company, acquires the HP plant from Ankur Drugs and Pharma Ltd. to increase production capacity https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd-to-increase-production-capacity-2/ Tue, 26 Apr 2022 10:52:04 +0000 https://pricesvardenafillevitra.com/akums-the-largest-pharmaceutical-contract-manufacturing-company-acquires-the-hp-plant-from-ankur-drugs-and-pharma-ltd-to-increase-production-capacity-2/ NNA | Update: April 26, 2022 4:20 p.m. STI New Delhi [India]April 26 (ANI/PNN): Akums Drugs & Pharmaceuticals Ltd., the largest pharmaceutical contract manufacturing company in India, recently acquired the facilities of Ankur Drugs and Pharmaceuticals Ltd. based in Himachal Pradesh.Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in India, recently acquired […]]]>



NNA |
Update:
April 26, 2022 4:20 p.m. STI

New Delhi [India]April 26 (ANI/PNN): Akums Drugs & Pharmaceuticals Ltd., the largest pharmaceutical contract manufacturing company in India, recently acquired the facilities of Ankur Drugs and Pharmaceuticals Ltd. based in Himachal Pradesh.
Akums Drugs & Pharmaceuticals Ltd, the largest pharmaceutical contract manufacturing company in India, recently acquired a facility from Ankur Drugs and Pharmaceuticals Limited. The facility acquired by Akums Drugs & Pharmaceuticals Ltd is one of the largest drug manufacturing facilities in the country.
With this acquisition, Akums will increase its production capabilities for general oral tablets and oral liquids. The planned capacities of the new facility are 6 billion units of tablets and 90 million units of oral fluids per year. This facility is expected to be fully operational by the end of 2022.
Founder, Developer and Director of Akums Drugs & Pharmaceuticals, Sandeep Jain said, “What adding this new facility to our existing network means is to intensify our ongoing efforts to serve our customers efficiently and better serve the nation. At Akums, are already leading the market in many areas and therefore we also know that there is still a lot to do.With this new facility at Nalagarh in Solan, Himachal Pradesh, we are trying to fill other gap capacity in the pharmaceutical industry. “
Founder, Promoter and Director of Akums Drugs & Pharmaceuticals, Sanjeev Jain said, “In 2021, our supplies accounted for approximately 12% of the total market. With this new acquisition of facilities in the state of Himachal Pradesh and our previous acquisition in Kotdwar, Uttarakhand, in August 2021, we have further strengthened our total capacity. This expansion is a step towards achieving our target of 20% market share. Operations at our Kotdwar plant recently commenced, while our new Himachal Pradesh plant is expected to start operations by December 2022.”

Apart from these changes, Akums had also acquired three API facilities near Chandigarh in January 2021, all of which contribute to building its capacity and efficient upstream integrated supply chain to strengthen its market leadership position in India, as Akums manufactures about 12% of all drugs consumed in the country.
Akums – Akums Drugs & Pharmaceuticals Ltd. is India’s largest pharmaceutical contract manufacturing company, manufacturing over 12% of Indian consumption. The organization is involved in the manufacture and export of formulations in a wide range of dosage forms and therapeutic segments.
The company currently supplies almost all Indian and multinational pharmaceutical companies across the world and is one of the largest employers. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta-lactum and non-beta-lactum formulations), oral liquid dosage forms, sterile dosage forms (injectable, ocular, ear and nasal) , hormonal (oral and injectable), ointments & cosmetics, Ayurvedic, food supplements & nutraceuticals and animal health care.
Within a few years, the organization has become the icon of India’s pharmaceutical industry and currently manufactures over 12% of the country’s total medical needs. With the creme de la creme of dedicated pharmaceutical staff and standardized practices, Akums has successfully achieved national and international accreditations and established trust based on efficacy, safety and quality.
The organization is certified by WHO-GMP, ISO 9001:2015, ISO 14001:2015 certificates and various international accreditations, such as; ANVISA, Brazil, NAFDAC, Nigeria, FDB, Ghana, PMPB, Malawi among others and exports to 53 countries around the world.
This story is provided by PNN. ANI shall in no way be responsible for the content of this article. (ANI/PNN)

]]>
Pharmaceutical company donates 60,000 boxes of medicine to Ukraine https://pricesvardenafillevitra.com/pharmaceutical-company-donates-60000-boxes-of-medicine-to-ukraine/ Mon, 25 Apr 2022 02:00:00 +0000 https://pricesvardenafillevitra.com/pharmaceutical-company-donates-60000-boxes-of-medicine-to-ukraine/ An East Midlands medicine manufacturer has donated nearly 60,000 boxes of essential medicines to war-affected people in Ukraine. Loughborough-based Morningside Pharmaceuticals has provided 1.29 million doses of the drug after founder and chairman Dr Nik Kotecha OBE DL spoke with British Ambassador to Ukraine Vadym Prystaiko. Dr Kotecha, who was recently made a second lieutenant […]]]>

An East Midlands medicine manufacturer has donated nearly 60,000 boxes of essential medicines to war-affected people in Ukraine.

Loughborough-based Morningside Pharmaceuticals has provided 1.29 million doses of the drug after founder and chairman Dr Nik Kotecha OBE DL spoke with British Ambassador to Ukraine Vadym Prystaiko.

Dr Kotecha, who was recently made a second lieutenant in Leicestershire, said: “The heartbreaking situation in Ukraine has affected us all and like so many people in the UK we have been keen to do all we can to help the victims of this terrible conflict.

“After speaking to the Ambassador, the Ukrainian Embassy has identified a range of drugs manufactured by Morningside that their healthcare system urgently needs.

“The Embassy and our teams at Morningside then worked closely with the UK Department of Health and Social Care (DHSC) to ensure the medicines could be dispatched quickly as humanitarian aid.

“I would like to thank our international, supply chain and warehousing teams for turning the situation around within days, to ensure that those who urgently need their medicines receive them as quickly as possible. “

Over the past three decades, Morningside has built a reputation as a supplier of pharmaceuticals and medical devices in the UK and overseas.

Dr Kotecha said the medicine shipment was transported in a secure, temperature-controlled environment to the embassy’s distribution center in Poland.

From there, the drugs are supplied to hospitals, health centers and patients across Ukraine, including the regions hardest hit by the Russian invasion.

Morningside has also supported the relief effort in Ukraine by stocking hundreds of packs of nappies, feminine hygiene packs, sleeping bags and children’s essentials in its Loughborough warehouse.

These goods were donated by members of the public through Polish Associations and Social Clubs in Loughborough and have now been delivered to support Ukrainian refugees in Poland.

Dr Kotecha said: “We all hope for a speedy resolution to the war in Ukraine, which will end the suffering and atrocities taking place there.

“There has been a huge outpouring of support for those caught up in this terrible conflict, and it has been humbling to see the enormous generosity of people in the UK for those suffering extreme and often life-threatening hardship, through no fault of their own. their part. ”

]]>
Pharmaceutical company settles for $10 million ahead of San Francisco opioid trial https://pricesvardenafillevitra.com/pharmaceutical-company-settles-for-10-million-ahead-of-san-francisco-opioid-trial/ Wed, 20 Apr 2022 23:26:10 +0000 https://pricesvardenafillevitra.com/pharmaceutical-company-settles-for-10-million-ahead-of-san-francisco-opioid-trial/ Pharmaceutical company settles for $10 million ahead of San Francisco opioid trial The city of San Francisco has agreed to a $10 million settlement with Endo Pharmaceuticals over the company’s role in the opioid epidemic. SAN FRANCISCO – The city of San Francisco has agreed to a $10 million settlement with Endo Pharmaceuticals over the […]]]>

The city of San Francisco has agreed to a $10 million settlement with Endo Pharmaceuticals over the company’s role in the opioid epidemic, five days before a federal civil case involving multiple drug companies goes to trial, reports said. officials announced Wednesday.

The settlement will separate Endo from Monday’s scheduled trial, which includes defendants like pharmaceutical giant Walgreens, as well as drug companies Allergan, Anda and Teva.

San Francisco City Attorney David Chiu alleges the defendants over-prescribed painkillers – driving patients addicted and fueling the illicit opiate markets that plague neighborhoods like the Tenderloin.

“The defendants in this case each contributed to and created this public nuisance by flooding San Francisco with opioids,” Chiu said at a press conference Wednesday. “Defendants did this by making false statements, misleading doctors and patients about the risks of opioids, and changing the general public’s view of opioid use.”

SEE ALSO: Fatal fentanyl overdoses in teens are on the rise

The case is just one of many where cities have sued drug companies for their role in the growing opioid crisis. The San Francisco case, however, is different, according to Chiu, because it involves defendants at all levels of the supply chain, including manufacturers, distributors and pharmacies.

He said the crisis has prompted users to seek out illegal opioids like heroin and fentanyl – pushing the number of overdose deaths in the city to almost 700 a year for the past three years.

In fact, between 2015 and 2020, opioid overdose deaths increased by 478%. And in 2020, opioid overdoses more than doubled Covid-19 deaths.

Between 2006 and 2014, drug companies dispensed more than 163 million pharmaceutical pain relievers in San Francisco, which equates to 22 pills per person per year, Chiu said.

“There’s a line you can draw between the conduct of legal businesses — manufacturers, distributors, and pharmacies — and the illegal markets you see today,” said Keith Humphreys, a Stanford professor who has studied the drug crisis. opioids. “They dodged not really loopholes but gaping holes in US regulations.”

Walgreens and other companies involved in the lawsuit would not comment.

The city attorney’s office filed the lawsuit in 2018 — and included companies like oxycontin maker Purdue Pharma.

Purdue filed for bankruptcy in 2020 and paid billions in settlements for its role in the opioid epidemic.

Chiu said the settlement with Endo has not been finalized but will include an upfront payment of $5 million.

Evan Sernoffsky is an investigative reporter for KTVU. Email Evan at evan.sernoffsky@fox.com and follow him on Twitter @EvanSernoffsky

]]>
Europe’s largest pharmaceutical company calls for interoperability – https://pricesvardenafillevitra.com/europes-largest-pharmaceutical-company-calls-for-interoperability/ Tue, 19 Apr 2022 11:55:39 +0000 https://pricesvardenafillevitra.com/europes-largest-pharmaceutical-company-calls-for-interoperability/ Ehab Youssef, Regional Manager Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more efficient global European healthcare system. COVID has brought to light the vulnerability of the healthcare system and the need for structural and technological change to help manage such a crisis. Although some regions have started […]]]>

Ehab Youssef, Regional Manager Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more efficient global European healthcare system.

COVID has brought to light the vulnerability of the healthcare system and the need for structural and technological change to help manage such a crisis. Although some regions have started to make the necessary changes, Youssef says Europe is lagging behind.

“In general, there is good progress in almost all countries. But the baseline is different depending on where each country stands on preparedness. Not all countries in Europe have the same level of access to digital tools and use of data,” says Youssef.

“The opportunity is huge, but it requires the work and support of everyone to make it happen: all stakeholders, including government, policymakers, pharmaceutical organizations and non-pharmaceutical organizations.”

There are some tentative efforts across Europe enabling interoperability to improve digital health infrastructure. Still, Youssef says there is still a lot to do and several hurdles need to be overcome.

Challenges and Opportunities

Today, two major obstacles exist within European healthcare: defining value and improving the digital approach.

“Generally, when looking at the healthcare system, waste is a big word – the ability of the system to define value, excluding treatment and excluding investment. And that’s one of the challenges. Sometimes the health system is in reactive mode or simply cutting costs. If your goal is just to save money, don’t deal,” says Youssef.

Ultimately, if a system is more efficient and, therefore, more efficient at bringing together solutions that allow for a smoother overall process, costs will inevitably decrease.

“Defining value and what value means to the system, I believe, is something very critical. Mainly due to economic pressure, systems are starting to realize that there is another way to handle this,” says Youssef.

Denmark has one of the best healthcare systems in the world. This is largely because it is usually a private/public partnership and multiple actors and stakeholders are involved in supporting the system and finding solutions.

Data is easily shared and leveraged for decision makers to gain insights that can help clinical research.

Some startups are even part of this partnership, helping to manage some of the chronic data management issues, such as data ownership, which is one of the areas of friction that keeps organizations in many countries from moving forward. far.

“They’re just working on anonymizing the data, merging the data, helping the infrastructure of the different systems across the country to read each other and really be able to understand better,” Youssef says.

“What I really like is that the government is funding a lot of this project. So there is a very high commitment and a very strong desire from the country to make it a result. And that is quite scalable.

Denmark is a country that is quite ahead of the others when it comes to guaranteed connectivity. Yet, with the right support in Europe, an exponential impact can advance the entire European healthcare system.

“What I really like is that the government is funding a lot of this project. So there is a very high commitment and a very strong desire from the country to make it a result. And that is quite scalable.

Increase interoperability

Currently, barriers are in place that make interoperability difficult in Europe. There is a lack of cohesion, which needs to change to make the system more efficient.

Advancing scalable projects capable of transferring data between different countries will allow regions to build on each other’s information rather than duplicating their efforts.

“One of the barriers in place is [the ability to] mobilize different countries through policies, system infrastructures and transferable experiences,” says Youssef.

“It is one of the challenges and, at the same time, an opportunity that I think the minute you agree to take advantage of it, the impact will be exponential and this transformation will go really fast. It exists today. now a window of opportunity thanks to the European Health Data Area (EHDS).”

The European Data Strategy and the European Commission (EC) created the EHDS as part of a strategic initiative.

EHDS is the first data space designed to foster the exchange of health data and support the search for new treatments, prevention strategies, medicines and medical devices while aiming to allow individuals the right to control their personal health data.

“EHDS is something that should help direct the right policies to the system across Europe, because it cannot happen on the basis of an individual candidate alone,” Youssef says.

“There is a need to have the right policies in place that encourage and improve people’s behaviors, people’s behavior, data sharing behavior, and give them confidence and the right level of privacy to give them the courage to change. these behaviors,” says Youssef.

In response to the EHDS initiative, a report by the Open Data Institute (ODI) highlighted the readiness of different countries to adopt and adapt health data.

“The ODI report has helped us see where the opportunities are and where the challenges are that I hope people can build on and rely on,” Youssef says.

How the pharmacy can help

With only 2-3% of the current level of available data being mined, there is substantial room for growth, and Youssef says the pharmaceutical industry could help make a significant impact.

“It’s really an invitation to all pharma companies to support this product-centric transaction and interaction with external roles and play a role in system support, ecosystem formation and system infrastructure. of health to make that leap and that value,” Youssef says. .

He says Roche has transformed the usual business model into two main touchpoints.

The first focuses on the patient journey through patient partnerships – identifying areas of challenge for specific patients and developing partnerships with different stakeholders outside of Roche to improve the patient journey.

The second focuses on the journey of the health system and the creation of health partnerships to build and personalize care.

Roche aims to treat individual patients with an abundance of data to shift the system from a reaction-based mode to a prevention mode, to help identify at-risk patients early in the process, says Youssef. .

“There are a multitude of opportunities if pharmaceutical organizations start to really look at these opportunities by devoting more resources to them and being more collaborative,” says Youssef. “It could be done easily if everyone cooperated well and helped the system work.”

To read the ODI report mentioned above, click here.

About the interviewee

Ehab Youssef is responsible for the Northern Europe area of ​​Roche Pharmaceuticals. He has over 20 years of experience in the pharmaceutical industry. In 2011, he started working at Roche Pharma as General Manager for Egypt. He then oversaw the Middle East sub-region before becoming its Sector Head, where he contributed to the advancement of different therapeutic areas, including neurosciences, oncology, women’s health and diabetes. . Ehab assumed his current role as Head of North Europe Area in October 2019. Ehab graduated from Harvard Business School’s General Management Program in 2009 and holds a BS in Pharmaceutical Sciences.

About the Author

Jessica Hagen is a freelance health and life sciences writer and project manager who has worked with virtual reality health companies, fiction/non-fiction writers, non-profit and for-profit organizations and government entities.

]]>